Vermont Center for Immunology and Infectious Diseases, Department of Medicine, Larner College of Medicine, The University of Vermont, Burlington, VT 05405.
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, United Kingdom.
J Immunol. 2019 Nov 1;203(9):2369-2376. doi: 10.4049/jimmunol.1900451. Epub 2019 Sep 23.
Lack of understanding of the nature and physiological regulation of γδ T cell ligands has considerably hampered full understanding of the function of these cells. We developed an unbiased approach to identify human γδ T cells ligands by the production of a soluble TCR-γδ (sTCR-γδ) tetramer from a synovial Vδ1 γδ T cell clone from a Lyme arthritis patient. The sTCR-γδ was used in flow cytometry to initially define the spectrum of ligand expression by both human tumor cell lines and certain human primary cells. Analysis of diverse tumor cell lines revealed high ligand expression on several of epithelial or fibroblast origin, whereas those of hematopoietic origin were largely devoid of ligand. This allowed a bioinformatics-based identification of candidate ligands using RNAseq data from each tumor line. We further observed that whereas fresh monocytes and T cells expressed low to negligible levels of TCR-γδ ligands, activation of these cells resulted in upregulation of surface ligand expression. Ligand upregulation on monocytes was partly dependent upon IL-1β. The sTCR-γδ tetramer was then used to bind candidate ligands from lysates of activated monocytes and analyzed by mass spectrometry. Surface TCR-γδ ligand was eliminated by treatment with trypsin or removal of glycosaminoglycans, and also suppressed by inhibition of endoplasmic reticulum-Golgi transport. Of particular interest was that inhibition of glycolysis also blocked TCR-γδ ligand expression. These findings demonstrate the spectrum of ligand(s) expression for human synovial Vδ1 γδ T cells as well as the physiology that regulates their expression.
由于对 γδ T 细胞配体的性质和生理调节缺乏了解,因此对这些细胞的功能仍不完全了解。我们开发了一种不依赖于方法来鉴定人类 γδ T 细胞配体,方法是从莱姆关节炎患者的滑膜 Vδ1 γδ T 细胞克隆中产生可溶性 TCR-γδ(sTCR-γδ)四聚体。sTCR-γδ 用于流式细胞术,最初定义了人肿瘤细胞系和某些人原代细胞的配体表达谱。对各种肿瘤细胞系的分析表明,几种上皮或成纤维细胞来源的细胞表达高配体,而造血来源的细胞则缺乏配体。这使得可以使用来自每种肿瘤系的 RNAseq 数据基于生物信息学来鉴定候选配体。我们进一步观察到,新鲜单核细胞和 T 细胞表达的 TCR-γδ 配体水平低至可忽略不计,而这些细胞的激活导致表面配体表达上调。单核细胞上的配体上调部分取决于 IL-1β。然后,使用 sTCR-γδ 四聚体结合激活的单核细胞裂解物中的候选配体,并通过质谱进行分析。用胰蛋白酶处理或去除糖胺聚糖可消除表面 TCR-γδ 配体,内质网-高尔基体运输的抑制也可抑制其表达。特别有趣的是,抑制糖酵解也可阻断 TCR-γδ 配体的表达。这些发现证明了人滑膜 Vδ1 γδ T 细胞的配体表达谱以及调节其表达的生理学。